Business Context and Reporting Period
This Form 8-K, filed on January 22, 2019, reports events occurring on January 15, 2019, for Lexaria Bioscience Corp. The filing details a strategic partnership with Altria Group, Inc. to fund research and development for Lexaria's DehydraTECH technology, specifically for oral nicotine delivery.
Key Financial Metrics and Transaction Terms
The filing describes a material definitive agreement rather than a standard financial reporting period. Key financial terms include:
- Initial Investment: Altria Ventures Inc. purchased 20 Class B membership units of Lexaria Nicotine LLC for US$1,000,000.
- Additional Funding Potential: Altria has the option to provide up to an additional US$12 million through phased private financings contingent on research milestones.
- Revenue Model: Lexaria Nicotine will receive royalties on net sales of nicotine products containing the licensed technology sold by Altria in the U.S. and globally.
- Equity Structure: Altria received a minority equity interest in Lexaria Nicotine LLC and warrants to acquire additional units based on research triggers.
The filing does not provide consolidated revenue, profit, cash flow, or debt figures for Lexaria Bioscience Corp. as a whole.
Material Changes and Agreements
The primary material change is the entry into four distinct agreements with Altria entities:
- Investment Agreement: Establishes the initial US$1 million capital injection and equity structure.
- Warrant and Option Agreement: Grants Altria warrants for additional equity (17.5% and 8.9% tranches) upon meeting Phase 1 and Phase 2 research objectives. It also grants Altria an exclusive option to purchase 100% of Lexaria Nicotine's Class A units after Phase 3 objectives are met.
- License Agreement: Grants Altria an exclusive license to use DehydraTECH technology in the U.S. and a non-exclusive license globally for oral nicotine products.
- LLC Agreement: Amends the governance of Lexaria Nicotine, allowing Altria to designate one manager initially, increasing to two or three managers upon exercise of warrant tranches.
Outlook, Risks, and Contingencies
Outlook and Milestones: The partnership is milestone-based. Future funding and equity dilution depend on Lexaria Nicotine satisfying specific research objectives (Phase 1, 2, and 3) within agreed timeframes. If Altria does not exercise its warrants upon trigger events, the U.S. technology license automatically becomes non-exclusive.
Risks and Contingencies:
- Valuation Contingency: The purchase price for the potential 100% acquisition of Lexaria Nicotine by Altria will be determined by a qualified appraiser based on fair market value at the time of the option exercise.
- License Exclusivity: Exclusivity in the U.S. is contingent on Altria exercising its warrant tranches; failure to do so results in a non-exclusive license.
- Confidentiality: Certain portions of the license and warrant agreements have been redacted and filed separately under confidential treatment requests.
Investor Verification Checklist
- Verify the specific "Research Objectives" defined in the Warrant and Option Agreement to assess the likelihood of triggering additional funding.
- Review the redacted portions of the License Agreement (Exhibit 10.2) to understand the exact royalty percentage and net sales definitions.
- Confirm the current cash position of Lexaria Bioscience Corp. to determine reliance on the initial US$1 million versus existing reserves.
- Monitor the timeline for Phase 1 Research Objectives to evaluate the risk of the U.S. license becoming non-exclusive.
- Assess the potential dilution impact on Lexaria Bioscience Corp. shareholders if Altria exercises the option to acquire 100% of Lexaria Nicotine.